Dr. Sally Greenberg began her statistical career in the pharmaceutical industry at Knoll Pharmaceutical Company in October, 1979, while writing her PhD dissertation at Carnegie-Mellon University. While at Knoll, she worked on several NDAs, including IV verapamil for PSVT, atrial fibrillation, and atrial flutter; oral verapamil for rest and effort angina, atrial arrhythmias, and hypertension; propafenone for ventricular arrhythmias; and collagenase for herniated discs. She went on to receive her PhD in Statistics in May, 1983, and moved to Palo Alto, CA to join Syntex Research in January, 1984.
Dr. Greenberg remained at Syntex Research for almost 12 years, honing her expertise in the cardiovascular area. She worked on and supervised work on numerous cardiovascular compounds, including nicardipine and ticlopidine. She first became a manager of statisticians in December, 1986, with responsibility for all CV and CNS compounds. In August, 1991, she was also given supervisory responsibility for SAS programmers. She was promoted to Statistical Research Director of the Cardiovascular and CNS Statistics Department in June, 1994. With Roche taking over Syntex in 1994, the focus of the Palo Alto site changed to early development. Consequently, Dr. Greenberg moved to Berlex Laboratories in Richmond, CA (a subsidiary of Schering AG) in October, 1995 to head their Statistics and SAS Programming Department. While at Berlex, she worked on Betaseron for multiple sclerosis, and a compound for acute stroke.
In December of 1997, Dr. Greenberg was given the opportunity to start a Biometrics and Clinical Data Management function at a cardiovascular start-up company, COR Therapeutics. She accepted that offer and stayed with COR (and later Millennium after Millennium bought COR) for 7 years. It was in those years that she got much more intimately involved in designing and conducting cardiovascular mega-trials. She had the opportunity to work extensively with the Duke Clinical Research Institute (DCRI) and the TIMI Group, as well as with other leaders in cardiology. It was also the first time that she had direct supervisory responsibility for the Data Management function.
IN 2003 Millennium decided to close the former COR Therapeutics site in South San Francisco. Dr. Greenberg stayed with Millennium until the site closed in June 2004, at which point she accepted the position of VP of Biostatistics and Clinical Information Systems with Scios, a wholly owned subsidiary of Johnson & Johnson. At Scios, she had the opportunity to lead the Biostatistics, Statistical Programming, and Clinical Data Management Departments consisting of approximately 40 employees and contractors. She also supported the Cardiovascular Licensing & Acquisition function for J&J. After two major reorganizations at J&J, her department was moved to Alza, and she reported into the PRD organization. She became VP of Biometrics for the West Coast Cardiovascular Franchise of J&J.
In December of 2007, J&J decided to essentially eliminate their pharmaceutical presence in the San Francisco area. Dr. Greenberg left J&J in February 2008 to become an independent statistical consultant, forming S. Greenberg Statistical Consulting Inc.
In addition to her extensive industry experience, Dr. Greenberg has also been very active in the Biostatistics community, holding numerous offices within the Biopharmaceutical Section of the American Statistical Association, serving as an Associate Editor for The American Statistician, and giving invited presentations for the ASA Joint Statistical Meetings, ENAR, and DIA. She is also well-known within the Academic Cardiology community, having collaborated with academic cardiologists on numerous clinical trials and publications.